GO:0031573 mitotic intra-S DNA damage checkpoint signaling: S-Phase Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031573 (mitotic intra-S DNA damage checkpoint signaling) is a biological process that slows DNA synthesis after DNA damage by preventing new origin firing and stabilizing slow replication forks.
• The ATR-Chk1 axis is the central signaling module of this checkpoint, and Chk1 inhibition abrogates the intra-S checkpoint and sensitizes tumor cells to DNA-damaging agents.
• The ATR/Chk1 pathway also maintains normal replication fork progression even during unperturbed S phase, so the checkpoint is not only a damage-response module.
• Loss of the intra-S checkpoint permits cells with damaged DNA to continue replication, contributing to genomic instability and cancer progression.
• p53 status modifies the cellular response to checkpoint abrogation, which is relevant to radiosensitization strategies.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of checkpoint genes and are supported by EDITGENE services.
Description
The mitotic intra-S DNA damage checkpoint signaling pathway, annotated as GO:0031573, is a biological process that slows DNA synthesis in response to DNA damage by preventing new origin firing and stabilizing slow replication fork progression. This checkpoint operates during S phase of the mitotic cell cycle and is a critical barrier against replication of damaged templates. The ATR-Chk1 signaling module is the core transducer of this response, and its activity is required both for damage-induced slowing of DNA synthesis and for normal replication fork progression under unperturbed conditions. Because the intra-S checkpoint coordinates replication with DNA repair, its dysfunction is directly linked to genomic instability and to the sensitivity of cancer cells to DNA-damaging chemotherapies and radiotherapy. Researchers study GO:0031573 to understand how cells preserve genome integrity, how checkpoint inhibitors can be used therapeutically, and how candidate genes causally contribute to checkpoint signaling.
mitotic intra-S DNA damage checkpoint signaling At A Glance
| GO ID | GO:0031573 |
|---|---|
| GO term | mitotic intra-S DNA damage checkpoint signaling |
| Ontology | biological_process |
| Synonym | intra-S DNA damage checkpoint; mitotic intra-S DNA damage checkpoint; signal transduction involved in intra-S DNA damage checkpoint; S-phase checkpoint |
| Major function | Slows DNA synthesis after DNA damage by preventing new origin firing and stabilizing slow replication fork progression |
| Core signaling module | ATR-Chk1 axis |
| Cell cycle context | S phase of the mitotic cell cycle |
| Disease relevance | Cancer, chemoresistance, radiosensitization |
| Research methods | Live-cell imaging, Chk1 inhibitors, CRISPR models, replication assays |
What Is GO:0031573?
GO:0031573 describes a mitotic cell cycle checkpoint that slows DNA synthesis when DNA damage is detected. It achieves this by preventing new replication origins from firing and by stabilizing replication forks that are progressing slowly. The term is synonymous with intra-S DNA damage checkpoint, mitotic intra-S DNA damage checkpoint, signal transduction involved in intra-S DNA damage checkpoint, and S-phase checkpoint. It is a biological process that couples DNA damage sensing to the regulation of DNA replication during S phase.
Why Is mitotic intra-S DNA damage checkpoint signaling Important in Cell Biology?
The intra-S DNA damage checkpoint is essential for maintaining genome integrity because it prevents cells from replicating damaged DNA, which would otherwise lead to mutations and chromosomal rearrangements. Pharmacological inhibition of Chk1, a key effector of this checkpoint, abrogates the intra-S checkpoint and sensitizes tumor cells to DNA-damaging agents such as gemcitabine and radiation. Understanding GO:0031573 therefore informs both fundamental cancer biology and the rational design of combination therapies that exploit checkpoint dependencies.
• Protects genome integrity by slowing DNA synthesis when DNA is damaged.
• Prevents new origin firing and stabilizes stalled or slow replication forks.
• Central to the mechanism of action of Chk1 inhibitors in cancer therapy.
• Modulates sensitivity to gemcitabine and other antimetabolites.
• Influences radiosensitization of tumor cells, with p53 status as a modifier.
• Maintains normal replication fork progression even without exogenous damage.
• Provides a therapeutic window for combining checkpoint inhibitors with DNA-damaging drugs.
• Is studied with live-cell imaging of DNA damage response proteins.
• Relevant to oxidative stress and chronic inflammation models such as ulcerative colitis.
• Supports CRISPR-based causal gene validation in checkpoint research.
What Happens During mitotic intra-S DNA damage checkpoint signaling?
DNA damage sensing and ATR activation
In simple terms: When DNA gets damaged during S phase, sensor proteins recognize the problem and switch on a signaling kinase called ATR.
The intra-S checkpoint is initiated when DNA damage or replication stress is detected during S phase. The ATR-Chk1 pathway is the principal signaling module that transduces this signal, and its activity is required for the checkpoint response. Live-cell imaging of DNA damage response proteins has been used to visualize the recruitment of these factors to damage sites.
Chk1 activation and signal amplification
In simple terms: ATR activates Chk1, which then spreads the stop signal to many downstream targets.
Chk1 is a checkpoint kinase that is phosphorylated and activated downstream of ATR. New insights into Chk1 function have established it as a central node in the DNA damage response signaling network, coordinating cell cycle arrest and repair. Chk1 activation is essential for the intra-S checkpoint to slow DNA synthesis.
Prevention of new origin firing
In simple terms: The checkpoint stops new replication start points from being used, reducing the amount of damaged DNA being copied.
A defining feature of GO:0031573 is the prevention of new origin firing. By blocking late origin activation, the checkpoint reduces the total rate of DNA synthesis and provides time for repair. This mechanism is conserved and is a key readout in studies of Chk1 inhibitors.
Stabilization of slow replication forks
In simple terms: The checkpoint also protects replication forks that are already moving slowly so they do not collapse.
In addition to blocking new origins, the intra-S checkpoint stabilizes slow replication fork progression. Evidence indicates that the ATR/Chk1 pathway maintains normal replication fork progression even during unperturbed S phase, highlighting a dual role in fork protection. Fork stabilization prevents fork collapse and DNA breakage.
Checkpoint recovery and cell cycle resumption
In simple terms: Once damage is repaired, the checkpoint is turned off so replication and the cell cycle can continue.
After DNA repair, checkpoint signaling must be attenuated to allow S phase completion. Chk1 activity is downregulated as part of recovery, and failure to properly resolve the checkpoint can lead to persistent arrest or genomic instability. The balance between checkpoint maintenance and recovery is a key determinant of cell fate after DNA damage.
Key Genes Involved in GO:0031573 mitotic intra-S DNA damage checkpoint signaling
The following genes and proteins are central to mitotic intra-S DNA damage checkpoint signaling (GO:0031573) and are commonly studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATR | Apical kinase that senses replication stress and activates Chk1 | Core initiator of the intra-S checkpoint; target for inhibitor studies |
| CHEK1 | Effector kinase that slows DNA synthesis and stabilizes forks | Central node of the DNA damage response; Chk1 inhibitors in cancer therapy |
| TP53 | Tumor suppressor that modulates checkpoint and apoptosis decisions | p53 status affects radiosensitization by checkpoint abrogation |
| RPA1 | Single-stranded DNA binding protein that recruits ATR | Required for damage sensing at stalled forks |
| RPA2 | ssDNA binding subunit of RPA | Marker of replication stress and ATR activation |
| TOPBP1 | Activator of ATR at damaged replication forks | Essential for ATR-Chk1 signaling |
| CLSPN | Adaptor that promotes Chk1 phosphorylation by ATR | Regulates checkpoint activation kinetics |
| HUS1 | Component of the 9-1-1 clamp complex | Supports ATR recruitment and checkpoint signaling |
| RAD9A | Component of the 9-1-1 clamp complex | DNA damage sensor in the intra-S checkpoint |
| RAD1 | Component of the 9-1-1 clamp complex | Required for checkpoint activation |
| CDC25A | Phosphatase targeted by Chk1 to prevent origin firing | Downstream effector of the intra-S checkpoint |
| CDC45 | Replication initiation factor regulated by checkpoint | Readout of origin firing suppression |
| MCM2 | Replicative helicase component phosphorylated by ATR | Marker of active intra-S checkpoint signaling |
| PCNA | Replication clamp modified after DNA damage | Links replication and damage tolerance |
| WEE1 | Kinase that regulates CDK activity and S phase progression | Therapeutic target in combination with Chk1 inhibition |
| ATM | Related kinase that cooperates with ATR in damage signaling | Context-dependent contribution to intra-S checkpoint |
| CHEK2 | Checkpoint kinase with overlapping functions | Modulates checkpoint and repair decisions |
How Is mitotic intra-S DNA damage checkpoint signaling Regulated?
The intra-S DNA damage checkpoint is regulated by the balance between ATR-Chk1 activation and phosphatase-mediated inactivation. Chk1 activity is controlled by phosphorylation downstream of ATR and by its own degradation and dephosphorylation during recovery. Pharmacological inhibition of Chk1 abrogates the checkpoint and sensitizes cells to DNA-damaging agents, demonstrating that checkpoint strength is a tunable determinant of drug response. p53 status further modulates how cells respond to checkpoint abrogation, influencing whether cells undergo arrest or death. In chronic oxidative stress models, repeated H2O2 exposure drives cell cycle progression despite damage, suggesting that checkpoint regulation can be overcome in inflammatory contexts.
mitotic intra-S DNA damage checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHEK1 | Cancer chemoresistance and checkpoint abrogation | Chk1 knockout or point-mutation cell lines treated with gemcitabine |
| TP53 | Radiosensitization and p53-dependent cell fate | p53 knockout or knock-in isogenic lines with radiation |
| ATR | Replication stress and genomic instability | ATR knockout or kinase-dead knock-in models |
| CDC25A | Origin firing control and S phase progression | CDC25A overexpression or point-mutation models |
| MCM2 | Replication stress markers in inflammation | Oxidative stress models with repeated H2O2 exposure |
Cancer and chemoresistance
The intra-S DNA damage checkpoint is frequently exploited by cancer cells to survive DNA-damaging chemotherapy. Chk1 inhibition abrogates the checkpoint and potentiates gemcitabine and other antimetabolites, defining a window of opportunity for combination scheduling. Loss of checkpoint function can also promote genomic instability and tumor progression.
Radiosensitization and p53 status
Checkpoint abrogation sensitizes tumor cells to radiation, and the magnitude of radiosensitization depends on p53 status. MET inhibition-associated checkpoint abrogation has been shown to radiosensitize tumor cells in a p53-dependent manner. This links GO:0031573 to precision radiotherapy strategies.
Chronic inflammation and oxidative stress
Repeated oxidative stress, as modeled by H2O2 exposure in ulcerative colitis models, drives cell cycle progression and may override normal checkpoint control. This suggests that chronic inflammation can dysregulate the intra-S checkpoint and contribute to disease-associated genomic damage.
From mitotic intra-S DNA damage checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CHEK1 required for the intra-S checkpoint? | CHEK1 knockout cell line with DNA damage and replication assays |
| Does a specific Chk1 phosphorylation site control fork stabilization? | CHEK1 point-mutation knock-in (phospho-dead or phospho-mimetic) |
| How does p53 status modify checkpoint abrogation? | TP53 knockout and isogenic wild-type knock-in lines |
| Can ATR-Chk1 signaling be visualized in live cells? | Tagged knock-in of ATR or Chk1 with fluorescent proteins |
| Does overexpression of CDC25A override the checkpoint? | CDC25A overexpression stable cell line |
| Which genes modify sensitivity to gemcitabine? | CRISPR library screening in combination with gemcitabine |
How to Study the mitotic intra-S DNA damage checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Recruitment and dynamics of DNA damage response proteins | Visualizing checkpoint activation at damage sites |
| DNA fiber assay | Replication fork progression and origin firing | Measuring intra-S checkpoint activity |
| Chk1 inhibitor treatment | Checkpoint abrogation and drug sensitization | Chemopotentiation studies with gemcitabine |
| CRISPR knockout | Loss-of-function effects on checkpoint signaling | Testing causal gene requirements |
| CRISPR library screening | Genome-wide modifiers of checkpoint and drug response | Identifying combination therapy targets |
| Western blot | Phosphorylation of Chk1, MCM2, and RPA2 | Monitoring checkpoint activation |
| Flow cytometry | Cell cycle distribution and S phase progression | Assessing checkpoint-mediated arrest |
| Oxidative stress models | Checkpoint response to chronic damage | Inflammation-associated cell cycle progression |
Live-cell imaging of DNA damage response proteins
Live-cell imaging in two and three dimensions allows visualization of DNA damage response protein recruitment and checkpoint activation dynamics. This approach has been used to track proteins at damage sites in real time.
Replication fork progression assays
DNA fiber assays and related replication assays measure fork progression and origin firing. These methods provided evidence that the ATR/Chk1 pathway maintains normal replication fork progression during unperturbed S phase.
Checkpoint abrogation with Chk1 inhibitors
Selective Chk1 inhibitors such as GNE-900 are used to abrogate the intra-S checkpoint and study chemopotentiation. Drug scheduling studies define the window of opportunity for combining Chk1 inhibitors with gemcitabine.
CRISPR-based functional genomics
CRISPR knockout and library screening enable systematic identification of genes that regulate the intra-S checkpoint and modify drug sensitivity. These approaches complement pharmacological and imaging studies.
How CRISPR Can Be Used to Study GO:0031573 mitotic intra-S DNA damage checkpoint signaling
Knockout
CRISPR knockout of CHEK1, ATR, or downstream effectors such as CDC25A provides a clean loss-of-function model to test whether a gene is required for the intra-S checkpoint. Knockout lines can be challenged with DNA-damaging agents and assessed by replication and phosphorylation assays.
Point Mutation
Point-mutation knock-in of specific phosphorylation sites in Chk1 or ATR allows dissection of signaling events that control fork stabilization versus origin firing. Phospho-dead and phospho-mimetic alleles are particularly useful for separating checkpoint functions.
Knock-in
Tagged knock-in of ATR, Chk1, or RPA subunits with fluorescent or affinity tags enables live-cell imaging and proteomic analysis of checkpoint complexes. This approach has been used to visualize DNA damage response proteins in real time.
Overexpression
Overexpression of CDC25A or other checkpoint antagonists can override the intra-S checkpoint and drive S phase progression despite damage. Such models are useful for studying checkpoint bypass and chemoresistance.
How EDITGENE Supports mitotic intra-S DNA damage checkpoint signaling Research
Researchers studying mitotic intra-S DNA damage checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, fork stabilization, or drug sensitivity. EDITGENE provides publication-ready CRISPR cell models and screening services to support these investigations.
Contact EDITGENE today to design your custom CRISPR model for mitotic intra-S DNA damage checkpoint signaling research.
Frequently Asked Questions About mitotic intra-S DNA damage checkpoint signaling
What is GO:0031573 mitotic intra-S DNA damage checkpoint signaling?
GO:0031573 is a biological process that slows DNA synthesis in response to DNA damage by preventing new origin firing and stabilizing slow replication fork progression.
What genes are involved in the intra-S DNA damage checkpoint?
Key genes include ATR, CHEK1, TP53, RPA1, RPA2, TOPBP1, CLSPN, HUS1, RAD9A, RAD1, CDC25A, CDC45, MCM2, PCNA, WEE1, ATM, and CHEK2.
How does Chk1 regulate the intra-S checkpoint?
Chk1 is activated downstream of ATR and coordinates cell cycle arrest, prevention of origin firing, and fork stabilization.
Why is the intra-S checkpoint important in cancer therapy?
Chk1 inhibition abrogates the checkpoint and sensitizes tumor cells to DNA-damaging agents such as gemcitabine and radiation.
What is the role of ATR in the intra-S checkpoint?
ATR is the apical kinase that senses replication stress and activates Chk1 to slow DNA synthesis.
How is the intra-S checkpoint studied experimentally?
Common methods include live-cell imaging, DNA fiber assays, Chk1 inhibitors, Western blot for phospho-Chk1, and CRISPR knockout models.
Does p53 status affect checkpoint abrogation?
Yes, p53 status modifies radiosensitization of tumor cells by checkpoint abrogation.
What is the difference between the intra-S checkpoint and the G2/M checkpoint?
The intra-S checkpoint operates during S phase to slow DNA synthesis, whereas the G2/M checkpoint prevents entry into mitosis after damage.
Can CRISPR be used to study the intra-S checkpoint?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models enable causal dissection of checkpoint genes.
What diseases are linked to intra-S checkpoint dysfunction?
Cancer chemoresistance, genomic instability, and inflammation-associated cell cycle dysregulation are linked to checkpoint dysfunction.
Conclusion
GO:0031573 mitotic intra-S DNA damage checkpoint signaling is a central biological process that protects genome integrity by slowing DNA synthesis after damage through prevention of origin firing and stabilization of replication forks. The ATR-Chk1 axis is the core signaling module, and its pharmacological inhibition has therapeutic potential in cancer, particularly in combination with DNA-damaging agents. CRISPR-based models, including knockout, point-mutation, knock-in, and overexpression, provide powerful tools to dissect the causal roles of checkpoint genes and to identify new targets for combination therapy.
References
- 1. Dai Y et al.. 2010. New insights into checkpoint kinase 1 in the DNA damage response signaling network.. Clin Cancer Res 16(2):376-83 PMID: 20068082
- 2. Carrassa L et al.. 2011. Unleashing Chk1 in cancer therapy.. Cell Cycle 10(13):2121-8 PMID: 21610326
- 3. Petermann E et al.. 2006. Evidence that the ATR/Chk1 pathway maintains normal replication fork progression during unperturbed S phase.. Cell Cycle 5(19):2203-9 PMID: 16969104
- 4. Beckta JM et al.. 2012. Two- and three-dimensional live cell imaging of DNA damage response proteins.. J Vis Exp PMID: 23052275
- 5. Mikami K et al.. 2015. Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.. Mol Cancer Res 13(12):1544-53 PMID: 26358474
- 6. Blackwood E et al.. 2013. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.. Mol Cancer Ther 12(10):1968-80 PMID: 23873850
- 7. Poehlmann A et al.. 2013. Repeated H2 O2 exposure drives cell cycle progression in an in vitro model of ulcerative colitis.. J Cell Mol Med 17(12):1619-31 PMID: 24118792
